Capital Flow Monitor · Sponsors · CIK 1898714
Bonum Therapeutics, Inc.
1150 EASTLAKE AVENUE E, SEATTLE, WA, 98109 · 206-888-8485
Biotechnology · Corporation· inc. DELAWARE true 2021
Fit score
—
Offering
$32.3M
Sold
$26.9M
% sold
83.3%
Investors
8
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-04-17 | D ·current | 506(b) | $32.3M | $26.9M | 83.3% | 8 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- John Mulligan — Executive Officer / Director / Promoter, Seattle, WA
- John McKearn — Director, Seattle, WA
- Monique Schiersing — Director, Seattle, WA
-
Nicholas Walrod — Director, Seattle, WA
1 other raise
- Claros Technologies, Inc. $46.9M of $55.0M · 85.3%
-
Karl Handelsman — Director, Seattle, WA
1 other raise
- Codon Innovation Fund I, LP $12.4M of $15.0M · 82.7%
- Diane Hollenbaugh — Executive Officer, Seattle, WA
- Neela Patel — Executive Officer, Seattle, WA
-
Mitchell Mutz — Director, Seattle, WA
1 other raise
- Omniox, Inc. $24.1M of $28.1M · 85.8%
-
Samuel Bjork — Director, Seattle, WA
1 other raise
- Elemental Machines, Inc. $5.7M of $5.7M · 100.0%
-
Gaurav Aggarwal — Director, Seattle, WA
5 other raises
- Vivo Opportunity Fund, L.P. $816.9M of —
- Vivo Drakkar Co-Invest Fund, L.P. $0 of —
- Vivo Opportunity Co-Invest (Cycle 3), L.P. $0 of —
- Vivo Capital Fund X, L.P. $717.0M of —
- Vivo Opportunity Cayman Fund, L.P. $148.5M of —
- Samuel Blackman — Director, Seattle, WA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.